https://www.selleckchem.com/pr....oducts/sch-527123.ht
ement other ways of preserving residual hearing and, hence, should deserve further clinical evaluation in CI patients. The Wnt/β-catenin pathway has been implicated in the development of adynamic bone disease in early-stage chronic kidney disease (CKD). Dickkopf-related protein 1 (DKK1) and sclerostin are antagonists of the Wnt/β-catenin pathway yet have not been widely used as clinical indicators of bone disease. This study characterized levels of DKK1, sclerostin, and other biomarkers of mineral metabolism in participants across a
Like
Comment
Share
